BEDFORD, Mass., May 7, 2012 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, is featuring minimally invasive technologies in surgical, diagnostic and skeletal health at The American College of Obstetricians and Gynecologists (ACOG) annual clinical meeting. Hologic is one of the largest exhibitors at ACOG, the nation's leading assembly of physicians providing healthcare for women. The meeting is in San Diego, CA May 5-9.
Hologic's GYN Surgical division is highlighting a family of newly developed educational tools and platforms for physicians performing hysteroscopic procedures. Shown for the first time at ACOG is the GyneSim hysteroscopic simulation platform, which provides best practices in training for the MyoSure tissue removal system, fluid management training and troubleshooting for physicians. The MyoSure tissue removal system is an innovative treatment that enables incision-less, fast removal of intrauterine tissue.
Also debuting is Hologic's new Aquilex fluid control system. This high performance system is designed to simplify hysteroscopic fluid management and optimize the MyoSure procedure.
The NovaSure procedure, along with our other procedures, is now featured on drawMD OB/GYN, an iPad application sponsored by Hologic. This iPad app is designed to enhance physician-patient communication by offering an easy, visual way of instantly explaining complex issues and the possible medical and surgical solutions. The app is a free download in the iTunes app store and in the Hologic booth.
Since the introduction of the ThinPrep Pap Test in 1996, Hologic has been dedicated to the prevention of cervical cancer through screening. Over half a billion ThinPrep Pap Testshave been shipped worldwide. Today the ThinPrep Pap Test is the most widely-used liquid based cytology platform in the United States and in many other countries around the world.
The Cervista HPV HR Test is the first high-risk HPV test designed to detect all 14 oncogenic strains of HPV, reduce false-positive results associated with low-risk cross reactivity, and provide an internal control to prevent false negatives. The Cervista HPV 16/18 Test is the first approved HPV genotyping test available in the United States designed to detect and differentiate highly ocogenic and persistent HPV types 16 and 18, which are associated with approximately 70 percent of cervical cancers.
Hologic's unique combination of cytology and molecular products, including the ThinPrep Pap, Cervista HPV HR and Cervista HPV 16/18 tests, provides a full range of cervical cancer screening technologies for improving women's health.
Hologic pioneered dual x-ray absorptiometry (DXA) technology, the industry standard for assessing bone health. At ACOG, the Hologic Skeletal Health division shows how clinicians using the Company's Discovery system can identify fractures not discernible by normal examinations and this same technology can measure body composition and support the diagnosis of heart disease. Hologic's new Advanced Body Composition assessment package offers the obesity and fitness markets the Company's whole body DXA systems which, up to now, have primarily been used to measure osteoporosis in women after they reach menopause.
About Hologic, Inc. Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast Magnetic Resonance Imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications.
Hologic, Advanced Body Composition, Aquilex, Discovery, GyneSim, MyoSure, NovaSure and ThinPrep are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries. All other trademarks, registered trademarks, and product names are the property of their respective owners.
Forward-Looking Statement Disclaimer: This News Release may contain forward-looking information that involves risks and uncertainties, including statements about litigation activities and the anticipated impact of those activities on the Company's results of operations. These forward-looking statements are based upon assumptions made by the Company as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. Additional proceedings, including appeals, on the referenced matters are possible which may affect the ultimate outcome of the litigation and associated liability. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based. Certain factors that could adversely affect the Company's business and prospects are described in Hologic's filings with the Securities and Exchange Commission.
SOURCE Hologic, Inc.